We also demonstrated that HX630 inhibited tumor growth in vivo and decreased pro-opiomelanocortin gene (Pomc) mRNA expression and in vitro. Thus, we provide new evidence that RXR agonists, especially HX630 could be new therapeutic candidates for Cushing’s disease [11]. The gene discussed is POMC; the disease is neoplasm.